首页> 外文OA文献 >Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy

【2h】

Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy

机译：基于Fludarabine的Veallus的切碎方案，或没有Rituximab的患者以前未经治疗的惰性淋巴瘤的患者：对安全性和疗效的回顾性分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Xiaoxiao Xu; Yizhuo Zhang; Zhengxing Wang; Xiaoxiong Wu; Yong Yu; Bei Yan;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 改良Hyper-CVAD方案治疗恶性淋巴瘤患者的安全性和疗效评价 [J] . 施薇, 杨晟, 桂琳, 癌症（英文版） . 2009,第010期
2. Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy [J] . Xiao-xiao Xu, Bei Yan, Zhen-xing Wang, OncoTargets and therapy . 2013,第3期

机译：先前未经治疗的惰性淋巴瘤患者中以氟达拉滨为基础的抗CHOP样方案与有或没有利妥昔单抗的方案：回顾性安全性和有效性
3. Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases. [J] . Yoko Hashimoto, Akihiko Yokohama, Akio Saitoh, Journal of clinical and experimental hematopathology : . 2013,第3期

机译：IL-2受体α（sIL-2Rα）的可溶形式的预后重要性及其与弥散性大B细胞淋巴瘤中接受或不使用利妥昔单抗的CHOP样方案治疗的淋巴瘤细胞的IL-2Rα（CD25）表面表达的关系： 338例的回顾性分析。
4. Prognostic Importance of the Soluble Form of IL-2 Receptorα (sIL-2Rα) and its Relationship with Surface Expression of IL-2Rα (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases [J] . Yoko Hashimoto, Akihiko Yokohama, Akio Saitoh, Journal of clinical and experimental hematopathology : . 2013,第3期

机译：IL-2受体α（sIL-2Rα）的可溶性形式对预后的重要性及其与弥漫性大B细胞淋巴瘤淋巴瘤细胞表面表达IL-2Rα（CD25）的关系，采用或不使用利妥昔单抗的CHOP样方案治疗： 338例回顾性分析
5. Efficacy and Safety of Right Versus Left Transradial Approach for Invasive Coronary Procedures in Octogenarian Patients [C] . Gomez-Blazquez I., Fernez-Barbeira S., Jimenez-Diaz V.A., International Congress on Coronary Artery Disease. . 2013

机译：术语术语患者侵袭性冠状动脉术治疗右颅跨度方法的疗效和安全性
6. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
7. Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy [O] . Xiao-xiao Xu, Bei Yan, Zhen-xing Wang, 2013

机译：先前未治疗的惰性淋巴瘤患者中以氟达拉滨为基础的治疗方案与有或没有利妥昔单抗的CHOP样治疗方案比较：安全性和有效性的回顾性分析
8. Prognostic Importance of the Soluble Form of IL-2 Receptor^^alpha; (sIL-2R^^alpha;) and its Relationship with Surface Expression of IL-2R^^alpha; (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases [O] . Yoko Hashimoto, Akihiko Yokohama, Akio Saitoh, 2013

机译：可溶性形式的IL-2受体^ ^α的预后重要性; （SIL-2R ^ ^ alpha;）及其与IL-2R ^ 表面表达的关系^ Alpha; （CD25）淋巴瘤在弥漫性大B细胞淋巴瘤中，用或不含rituximab处理的切碎方案治疗：338例的回顾性分析

Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy

著录项

引文网络

相似文献

相关主题

期刊订阅